Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
46-60 of 72
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
- advertisement
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Significance of HER2 Expression in Solid Tumors
MinuteCE®Significance of HER2 Expression in Solid Tumors
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®Diversity in HER2 Expression Among Gynecologic Cancers
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
- advertisement
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
